Corient Private Wealth LLC Invests $394,000 in Scholar Rock Holding Co. (NASDAQ:SRRK)

Corient Private Wealth LLC bought a new position in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 9,120 shares of the company's stock, valued at approximately $394,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Quarry LP lifted its holdings in Scholar Rock by 3,443.3% during the 3rd quarter. Quarry LP now owns 4,500 shares of the company's stock worth $36,000 after buying an additional 4,373 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after buying an additional 766 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Scholar Rock by 1,321.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after acquiring an additional 1,031 shares during the last quarter. Finally, Amalgamated Bank increased its holdings in shares of Scholar Rock by 30.6% in the 4th quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after acquiring an additional 620 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Katie Peng sold 1,006 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now owns 30,319 shares in the company, valued at $1,043,579.98. This represents a 3.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Tracey Sacco sold 6,500 shares of the firm's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total transaction of $215,020.00. Following the transaction, the insider now directly owns 71,750 shares in the company, valued at $2,373,490. The trade was a 8.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 299,772 shares of company stock worth $11,245,798 in the last quarter. 19.20% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a report on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock currently has an average rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Stock Performance

Shares of SRRK traded down $1.84 during midday trading on Thursday, reaching $30.70. 995,580 shares of the stock were exchanged, compared to its average volume of 1,182,529. The company has a market capitalization of $2.91 billion, a price-to-earnings ratio of -13.06 and a beta of 0.56. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The business's 50-day moving average price is $36.64 and its 200 day moving average price is $33.52.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.